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The diagnosis and assessment of pulmonary arterial hypertension is a rapidly evolving area, with changes occur-
ring in the definition of the disease, screening and diagnostic techniques, and staging and follow-up assessment.
The definition of pulmonary hypertension has been simplified, and is now based on currently available evidence.
There has been substantial progress in advancing the imaging techniques and biomarkers used to screen pa-
tients for the disease and to follow up their response to therapy. The importance of accurate assessment of right
ventricular function in following up the clinical course and response to therapy is more fully appreciated. As new
therapies are developed for pulmonary arterial hypertension, screening, prompt diagnosis, and accurate assess-
ment of disease severity become increasingly important. A clear definition of pulmonary hypertension and the
development of a rational approach to diagnostic assessment and follow-up using both conventional and new
tools will be essential to deriving maximal benefit from our expanding therapeutic armamentarium. (J Am Coll
Cardiol 2009;54:S55–66) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.011b
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jefinition of Pulmonary Hypertension (PH)
H has been defined as a resting mean pulmonary arterial
ressure (mPAP) 25 mm Hg, or an mPAP with exercise
30 mm Hg. The subgroup of PH known as pulmonary
rterial hypertension (PAH) adds the criterion that the
ulmonary arterial wedge pressure must be 15 mm Hg.
ome definitions have also included pulmonary vascular
esistance (PVR), requiring that it be 2 or 3 Wood units.
otential weaknesses of the current definition include the
act that the level, type, and posture of exercise have not
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rterial pressure (PAP) varies with age (1).
Clarification of the definition based on available evidence
as an important initial objective of the 4th World Sym-
osium on Pulmonary Hypertension, which took place in
ana Point, California, in early 2008. Members of the
orking Group on Diagnosis and Assessment of PAH
eviewed the literature and identified 47 studies describing
2 populations of healthy volunteers that were examined for
AP during rest and physical exercise (2–51). Normal
esting mPAP was approximately 14  3.3 mm Hg. The
pper limit of normal (ULN) was approximately 20.6 mm
g. During slight exercise (heart rate [HR] 100 to 110
eats/min), the ULN for mPAP was 32 (supine) and 30 mm
g (upright). During submaximal exercise (HR 130 to 135
eats/min), the ULN was 31 (supine) and 35 mm Hg
upright), and during maximal exercise (HR 160 beats/min),
t was 37 (supine) and 35 mm Hg (upright). If only studies
ere considered that strictly excluded exercise-induced hyper-
ension, the data were not significantly different (1).
According to age group, there were only minor differ-
nces in PAP at rest; however, during slight and submaxi-
al exercise, mPAP was significantly higher in older sub-
ects (50 years old). During slight exercise, the ULN was
9 and 30 mm Hg for people age 30 and 30 to 50 years,
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50 years, the ULN was 45 mm
Hg. During submaximal exercise,
the ULN for subjects age30, 30
to 50, and 50 years were 33, 36,
and 47 mm Hg, respectively.
Recommendations. Based on
this literature review, we recom-
mend simplifying the definition
of PH, as follows:
• The exercise and PVR criteria
should be eliminated.
• A resting mPAP of 8 to 20
mm Hg should be considered
normal, based on available ev-
idence.
• The proposed new definition
of PH is a resting mPAP 25
mm Hg.
Further studies are needed to
better determine the natural his-
tory of patients with mPAP 21 to
24 mm Hg.
Screening and Diagnosis
Noninvasive estimation of PAP—
echocardiography. With the in-
troduction of Doppler echocardi-
ography, approximate evaluation
of PAP became feasible. Al-
though this method is helpful in
detecting or excluding significant
PH, its intrinsic and operator-
dependent limitations make early
PH diagnosis and screening
challenging (52,53). In the pres-
ence of a tricuspid insufficiency
peak gradient (TIPG) 30 mm
Hg, some investigators have used
arbitrary criteria for noninvasive
diagnosis of PH (54). During a
meeting on PH held in Evian,
France, in 1998, mild PH was
arbitrarily defined as a tricuspid
jet velocity (TJV) 2.8 to 3.4 m/s,
which corresponds to TIPG 31
to 46 mm Hg and to PAP 36 to
51 mm Hg, if a fixed right atrial
pressure (RAP) estimate of 5
m Hg is used (55). It seems reasonable to consider TJV
2.8 m/s and TIPG31 mm Hg at rest as elevated, except
n elderly and/or very obese patients (56) (Table 1).
Two large French studies have attempted prospective
Abbreviations
and Acronyms
6MWD  6-min walk
distance
BNP  brain natriuretic
peptide
CMR  cardiac magnetic
resonance
CO  cardiac output
CPET  cardiopulmonary
exercise testing
FC  functional class
HR  heart rate
IPAH  idiopathic
pulmonary arterial
hypertension
LV  left ventricle/
ventricular
mPAP  mean pulmonary
arterial pressure
NIH  National Institutes
of Health
NT-proBNP  N-terminal
pro-brain natriuretic peptide
NYHA  New York Heart
Association
PAH  pulmonary arterial
hypertension
PAP  pulmonary arterial
pressure
PH  pulmonary
hypertension
PVR  pulmonary vascular
resistance
RA  right atrial/atrium
RAP  right atrial pressure
RCT  randomized
controlled trial
RHC  right heart
catheterization
RV  right ventricle/
ventricular
SSc  systemic sclerosis
TAPSE  tricuspid annular
plane systolic excursion
TIPG  tricuspid
insufficiency peak gradient
TJV  tricuspid jet velocity
ULN  upper limit of
normalerification of abnormal echocardiographic results, both paking into account the presence of dyspnea. The ItinerAIR
tudy (57) enrolled 599 patients with scleroderma. In
atients with TJV 3.0 or with dyspnea and TJV 2.5 to 3.0
/s, right heart catheterization (RHC) was performed,
egardless of symptoms. Among the 33 patients who met
hose criteria, 14 had mild to moderate PH on RHC at rest,
nd an additional 4 developed mPAP 30 mm Hg at
xercise. These results were compatible with the 45%
alse-positive results seen with echo-Doppler screening.
he second trial assessed the prevalence of PAH in patients
ith human immunodeficiency virus infection (58); 10% of
atients presented with dyspnea, and 247 were included in
he screening program and were eligible for echocardiogra-
hy. Among 18 patients with TJV 2.5 m/s, only 5 were
ound to have PAH on RHC. The results should be
nterpreted with caution because the sensitivity of echocar-
iography for the detection of PH in this setting is not
nown.
Doppler echocardiography may be performed during
xercise to estimate PAP. One report found an excellent
orrelation with catheter measurements of PAP performed
imultaneously (r  0.98) (59). Exercise echocardiography
as been used to assess systolic PAP 40 mm Hg in several
roups of patients (60), including those with chronic lung
isease, heart transplantation (61), atrial septal defect (62),
nd susceptibility to high-altitude lung edema (63), as well
s asymptomatic carriers of a PH gene mutation (60). In all
roups, PAP significantly increased during exercise com-
ared with control subjects (63). One group has arbitrarily
efined systolic PAP 40 mm Hg, calculated after assum-
ng fixed RAP of 5 mm Hg, as a normal hemodynamic
esponse to exercise (60). A multicenter trial that used
xercise echocardiography to assess genetic predisposition to
AH among family members of index patients with idio-
athic pulmonary arterial hypertension (IPAH) found more
ronounced rise of Doppler-derived systolic PAP in family
embers compared with healthy control subjects (64).
ew modalities in noninvasive screening. Cardiac mag-
etic resonance (CMR) may offer more reliable data both at
est and during exercise or acute vasodilator testing, but so
ar it cannot be used as a screening test. Biomarkers, such as
eference Ranges for Normal Systolic Pressureradi ts Assessed With Doppler Betwe n RVnd RA (TIPG)
Table 1
Reference Ranges for Normal Systolic Pressure
Gradients Assessed With Doppler Between RV
and RA (TIPG)
95% CI for TIPG (mm Hg)
Age (yrs) n Women (n  2,065) Men (n  1,147)
20 856 8.6–24.2 8.2–26.2
20–29 669 9.2–24.4 9.9–26.3
30–39 650 9.3–25.7 8.7–27.5
40–49 494 9.9–27.5 9.1–28.3
50–59 344 10.2–29.4 11.0–30.6
60 199 10.5–32.1 11.2–33.6
ata have been extracted from a table in McQuillan et al. (56) and used with permission.
CI  confidence interval; RA  right atrium; RV  right ventricle; TIPG  tricuspid insufficiency
eak gradient.
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June 30, 2009:S55–66 Diagnosis and Assessment of PAHrain natriuretic peptide (BNP) and N-terminal pro-brain
atriuretic peptide (NT-proBNP), may be useful in early
etection of PAH. In an otherwise healthy, young, and
ildly symptomatic person with borderline echocardio-
raphic results, elevated BNP levels may justify follow-up.
revalence and characteristics of PH in selected associ-
ted conditions. The prevalence of PAH varies substan-
ially depending on the type, etiology, and underlying
ondition. Table 2 is a summary of the best available data
rom a variety of sources (57,65–95).
enetic assessment and counseling. Genetic testing is
iscussed in another section of this supplement (95). When
esting and counseling are performed for genetic mutations,
hey should be done as part of a comprehensive program that
ncludes discussion of the risks, benefits, and limitations of
he test results. When used for genetic testing and counsel-
ng, molecular testing for the mutation should be performed
revalence and Characteristics of PH in Associated Conditions
Table 2 Prevalence and Characteristics of PH in Associated Co
Condition
PAH 15/million (65)
IPAH 5.9/million (65)
FPAH Vanderbilt: 107 U.S. families (300 PAH p
(James Loyd, MD, personal communic
Columbia: 100 U.S. families (353 PAH pa
behalf of Jane Morse, MD [deceased]
Utah: 28 U.S. families (C. Gregory Elliott,
Possible overlap between registries
APAH–scleroderma Prospective echocardiographic study of s
RVSP 40 mm Hg) of combined prev
8 Canadian CTD centers: PH detected on
26% of diffuse scleroderma patients
Prospective study in French registry, 599
suspected by echocardiography (VTR
mm Hg) on RHC. Thus, 47 of 599 (8%
18.3% (36 of 97) moderate–severe PH su
RHC in 89% (68); PH in 12 of 67 (17.
Portopulmonary
hypertension
PAH in 1% to 6% of patients with portal h
8.2% (101 of 1,235) of candidates for OL
of these 66 had PAH (others had PH
of 1,235 (5.3%) (73).
HIV 0.5% estimate (74,75)
CTEPH 0.8% of patients after first pulmonary em
At 1 year after pulmonary embolism, 44%
In another study of 223 PE patients, 3.1%
Sickle cell disease 32% of sickle cell patients have TRV 2.
Further hemodynamic studies may be ne
Thyroid diseases PH can be detected in up to 41% of patie
responds to treatment of the thyroid d
Schistosomiasis 20.6% of 34 patients with S. mansoni po
In an endemic area of Brazil, those with P
PH (69%) (25% of the screened popu
In 2 Brazilian PH centers, 30% of 123 ca
Myeloproliferative disorders Literature does not provide meaningful d
Post-splenectomy 11.5% of IPAH patients have had splenec
8.6% of CTEPH patients have had splene
Splenectomy is associated with an odds
n CTD patients who are newly screened with echocardiography, the degree of PAH, if present, d
cleroderma 210 to 276/million (68) and U.S. population of 302 million, the number of scleroderm
y right heart catheterization criteria. In African Americans, 0.15% have sickle cell disease (homo
APAH associated pulmonary hypertension; CTD connective tissue disease; CTEPH chronic
mmunodeficiency virus; ILD  interstitial lung disease; IPAH  idiopathic pulmonary arterial hype
rthotopic liver transplantation; PAH  pulmonary arterial hypertension; PAWP  pulmonary capillary w
atheterization; RV  right ventricular; RVSP  right ventricular systolic pressure; TRV  tricuspid regurgnly in a clinically approved and certified molecular genetics
aboratory.
taging and Follow-Up Assessment
rognostic parameters. Although the tools used to diag-
ose and assess patients with PAH have improved, the
umber and complexity of therapeutic interventions have
ncreased, making it even more challenging to accurately
redict prognosis. The American College of Chest Physi-
ians Evidence-Based Clinical Practice Guidelines on
AH, published in 2004, provide an excellent review of
rognosis in PAH (96). Following is an update to that
eview.
urvival in PAH. HISTORICAL PERSPECTIVE. The natural
istory of IPAH was described in the National Institutes of
ealth (NIH) registry, which followed up 194 patients
ons
Prevalence
among 2,300 individuals; includes 1 kindred with 19 women and 2 men)
February 2008)
among 3,400 individuals) (personal communication from Robyn J. Barst, MD on
ary 2008)
rsonal communication, February 2008)
rma and MCTD in 50 U.S. community practices: prevalence of PH (estimated
screened and unscreened patients  26.7% (66).
ardiography (RVSP 30 or 35 mm Hg depending on center) in 21% of limited and
derma patients without severe lung dysfunction: 29 had known PH, 33 more
/s or 2.5 m/s with unexplained dyspnea); 18 of 33 had PAH (mPAP 30  9
confirmed PAH. Patients with known PAH had mPAP 49  17 (57).
ed in patients who had screening echocardiography (retrospective); confirmed by
tients without ILD vs. 24 of 110 (21.8%) patients with ILD (69).
nsion (70–72).
echocardiographic RVSP 50 mm Hg; of these 90 had RHC mPAP 25 mm Hg;
ed by high cardiac output or PAWP), so prevalence of PAH in OLT candidates is 66
(76)
evidence of RV dysfunction and PH; 5.1% (4 of 78) had confirmed CTEPH (77).
year and 3.8% at 2 years had CTEPH after PE (78).
and 9% 3.0 m/s (80,81,95).
y to better characterize pulmonary hypertension in sickle cell disease.
th hyperthyroidism (82) and 49% of those with hypothyroidism (83), and usually
(84,85).
pertension had mPAP 20 mm Hg (11.8% 25 mm Hg) (86).
echocardiography had a higher prevalence of S. mansoni (80%) than those without
of 246 people had PH by the echocardiographic criteria) (87).
re associated with schistosomiasis (50% IPAH and 10% CTD) (88).
,90).
(91).
(vs. 2.5% among IPAH patients in this study) (92).
f 13 for development of CTEPH after pulmonary embolism (93).
d at RHC is usually mild, and the future course is unknown. Based on estimated prevalence of
s is 250  302  75,500, so approximately 7,550 (10%) people would be expected to have PAH
) and 8% have sickle cell trait (heterozygotes).
oembolic pulmonary hypertension; FPAH familial pulmonary arterial hypertension; HIV human
n; MCTD  mixed connective tissue disease; mPAP  mean pulmonary arterial pressure; OLT nditi
atients
ation,
tients
, Febru
MD, pe
clerode
iously
echoc
(67).
sclero
3.0 m
) had
spect
9%) pa
yperte
T had
explain
bolism
have
at 1
5 m/s
cessar
nts wi
isease
rtal hy
H by
lation
ses we
ata (89
tomy
ctomy
ratio o
etecte
a case
zygotes
thromb
rtensioedge pressure; PE  pulmonary embolism; PH  pulmonary hypertension; RHC  right heart
itation velocity; VTR  peak velocity of tricuspid regurgitation.
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Diagnosis and Assessment of PAH June 30, 2009:S55–66nrolled at 32 centers from 1981 to 1985 (97). The
stimated median survival was 2.8 years, with 1-, 3-, and
-year survival rates of 68%, 48%, and 34%, respectively.
urvival in associated PAH has also been evaluated. Stupi
t al. (98) reported a 2-year survival of 40% among patients
ith scleroderma and isolated PAH. Several series have
uggested that patients with scleroderma-associated PAH
ave a worse prognosis than those with IPAH, with hazard
atios for death ranging from 2.32 to 2.9 (99,100). In
ontrast, patients with PAH occurring in association with
ongenital heart disease have a better prognosis. Hopkins
t al. (101) described an actuarial survival in patients with
isenmenger syndrome who did not receive transplantation
f 97%, 89%, and 77% at 1, 2, and 3 years, respectively,
ompared with 77%, 69%, and 35% at 1, 2, and 3 years for
atients with IPAH. A national registry in France showed a
-year survival rate in PAH of 88% in the incident cohort (65).
HE IMPACT OF MEDICAL THERAPY. An open-label, random-
zed controlled trial (RCT) involving 81 IPAH patients
howed a survival advantage with epoprostenol therapy over
period of 12 weeks (102). Subsequent longer-term case
eries have compared survival on epoprostenol therapy with
istorical control subjects or with predictions based on an
quation described in the NIH registry study discussed
bove (97). Shapiro et al. (103) reported 1-, 2-, and 3-year
urvival rates in IPAH patients treated with epoprostenol of
0%, 76%, and 49%, respectively. Sitbon et al. (104)
ollowed up 178 patients and reported survival rates at 1, 2,
, and 5 years of 85%, 70%, 63%, and 55%. McLaughlin
t al. (105) reported on 162 patients with IPAH treated
ith epoprostenol. Observed survival rates at 1, 2, 3, 4, and
years were 88%, 76%, 63%, 56%, and 47%, respectively. A
ecent meta-analysis of RCTs in PAH, conducted by Galie
t al. (106), suggested that active treatments were associated
ith a reduction in mortality of 43% (relative risk: 0.57; 95%
onfidence interval: 0.35 to 0.92; p  0.023).
The effects of anticoagulant therapy on survival in pa-
ients with IPAH have been evaluated in 2 studies. Fuster
t al. (107) reported an apparent survival benefit of warfarin
n a retrospective, uncontrolled, single-center study of 120
atients. Rich et al. (108) described a better outcome among
atients treated with warfarin who were not calcium-
hannel blocker responders. The 1-, 3-, and 5-year survival
ates in patients treated with warfarin were 91%, 62%, and
7%, respectively, compared with 52%, 31%, and 31% in
hose not treated with warfarin.
McLaughlin et al. (109) reported that first-line therapy
ith bosentan, with the subsequent addition of or transition
o other therapy as necessary, resulted in Kaplan-Meier
urvival estimates of 96% at 12 months and 89% at 24
onths, compared with predicted survival rates from the
IH registry formula of 69% and 57%, respectively. Sitbon
t al. (110) compared survival in patients with WHO
World Health Organization) functional class (FC) III
PAH treated with bosentan with historical data from pimilar patients treated with epoprostenol. Kaplan-Meier
urvival estimates at 1 and 2 years were 97% and 91%,
espectively, in the bosentan cohort, and 91% and 84% in
he epoprostenol cohort.
esting to predict prognosis in PAH. HEMODYNAMICS. The
IH registry (97) suggested that 3 hemodynamic variables
ere associated with increased risk of death: increased PAP,
ncreased RAP, and decreased cardiac index. Sandoval et al.
111) reported on 61 IPAH patients and found that
ncreased mean RAP, decreased cardiac index, and de-
reased mixed venous oxygen saturation were predictive of
urvival. Other studies evaluated prediction of survival in
PAH based on hemodynamics (112–115). With 1 excep-
ion (112), lower cardiac output (CO) or cardiac index
eems to have been predictive. The prognostic value of
aseline hemodynamics may be impacted by epoprostenol
herapy. Sitbon et al. (104) found that lower mPAP and
igher mean RAP had negative prognostic implications by
nivariate analysis, whereas only mean RAP was predictive
y multivariate analysis. In 162 patients with IPAH treated
ith epoprostenol, McLaughlin et al. (105) found that only
ean RAP was predictive of survival in a univariate analysis.
ESPONSE TO ACUTE VASODILATOR THERAPY. Sitbon et al.
116) reported the results of a retrospective analysis of 557
PAH patients tested acutely with intravenous epoprostenol
r inhaled nitric oxide. Using a definition of a 20%
ecrease in mean PAP and PVR, only 70 patients (12.6%)
howed vasoreactivity. Long-term calcium channel blocker
esponders were defined as patients in New York Heart
ssociation (NYHA) FC I or II with sustained hemody-
amic improvement after at least 1 year without the addi-
ion of other PAH-specific therapy. Of the 70 patients
howing acute vasoreactivity, only 38 (6.8% of the overall
tudy group) had a favorable long-term response to calcium-
hannel blocker therapy.
CHOCARDIOGRAPHY. An early study of patients with
PAH in the late 1980s showed the severity of pericardial
ffusion to be predictive (117). Hinderliter et al. (118)
nalyzed the echocardiograms of 79 of 81 IPAH patients
ho participated in an RCT of epoprostenol (102) and
ound pericardial effusions in 43 patients. Larger effusions
orrelated with more severely impaired exercise performance
nd right atrial (RA) dilation. Effusion size was correlated
ith death or a composite of death or lung transplantation
t 1 year. Longer follow-up showed that the presence of a
ericardial effusion and RA area index were predictive of
urvival (119). A series of 53 IPAH patients showed the
alue of the right ventricular (RV) index (120). These
tudies suggest that pericardial effusion, indexed RA area,
nd RV index have prognostic value.
More recent studies have suggested that novel echocar-
iographic parameters might be of value. Forfia et al. (121)
eported that tricuspid annular plane systolic excursion
TAPSE) predicted survival in PH. In a cohort of 63
atients with PH, a TAPSE 1.8 cm was associated with
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June 30, 2009:S55–66 Diagnosis and Assessment of PAHreater RV systolic dysfunction. In patients with PAH (n
7), survival estimates at 1 and 2 years were 94% and 88%,
espectively, in subjects with a TAPSE 1.8 cm, and 60%
nd 50%, respectively, in subjects with a TAPSE 1.8 cm.
urudevan et al. (122) reported that in 50 patients with
uspected chronic thromboembolic PH, the systolic velocity
f the tricuspid annulus had an inverse relationship with
PAP and PVR. Mahapatra et al. (123) found that a
easure of pulmonary vascular capacitance, as determined
y Doppler echocardiography, is a predictor of mortality in
atients with IPAH and adds prognostic value to conven-
ional risk markers.
XERCISE CAPACITY. Measurements of exercise capacity in
AH have generally included 6-min walk distance
6MWD) and bicycle ergometry cardiopulmonary exercise
esting (CPET). Miyamoto et al. (124) compared these
easures in 27 patients with IPAH and found good
orrelation between maximum oxygen consumption and
MWD. The 6MWD is simpler to perform and reproduc-
ble. Barst et al. (102) used 6MWD as the primary outcome
easure in an RCT of chronic epoprostenol therapy in 81
atients with IPAH. The 6MWD was less in the nonsur-
ivors versus the survivors from both treatment groups, and
t was found to be an independent predictor of survival.
iyamoto et al. (124) studied 43 patients with IPAH.
atients walking fewer than 332 m had a significantly lower
urvival rate than those walking farther than 332 m. In a
tudy of long-term intravenous epoprostenol therapy in
atients with IPAH, Sitbon et al. (104) reported that a
MWD of 250 m was associated with a poor outcome.
umbert et al. (65) reported the results of a French registry
n PH, showing that the 6MWD correlates with NYHA
C in all forms of PAH. A number of important studies in
AH have used the 6MWD as the primary outcome
easure (102,125–132) or an important part of the primary
nd point (133). Wensel et al. (134) studied 86 patients with
PAH, 70 of whom were able to undergo CPET, and found
hat maximum oxygen consumption was an independent
redictor of survival.
C. In the NIH registry of patients with IPAH (before
odern therapy), the risk of death was higher among
atients in NYHA FC III or IV than among those in FC I
r II (97). Median survival was nearly 6 years among those
n NYHA FC I or II, 2.5 years among those in FC III, and
months among those in FC IV. A study of 91 patients
ith PAH, all treated with epoprostenol, showed that
atients in WHO FC IV, compared with FC I, II, and III,
ad a significantly decreased survival (99). In a study of 178
atients with IPAH treated with epoprostenol, Sitbon et al.
104) reported that survival was lower for those starting
herapy in NYHA FC IV compared with FC III, and that
he persistence of FC III or IV after 3 months of therapy
as associated with poor survival. aIOMARKERS—BNP. Nagaya et al. (135) measured BNP in 60
atients with IPAH at diagnostic catheterization, together
ith atrial natriuretic peptide, norepinephrine, and epi-
ephrine. According to multivariate analysis, baseline
lasma BNP was an independent predictor of mortality.
atients with a supramedian baseline BNP (150 pg/ml)
ad a significantly lower survival rate than those with an
nframedian level, according to Kaplan-Meier survival
urves (p  0.05). The BNP in survivors decreased signif-
cantly during the follow-up (217  38 pg/ml to 149  30
g/ml, p  0.05), whereas that in nonsurvivors increased
365  77 pg/ml to 544  68 pg/ml, p  0.05).
Fijalkowska et al. (136) found that NT-proBNP levels
orrelated with 6MWD, cardiac index, PVR, and RAP, but
ot with PAP in 55 patients. The NT-proBNP levels were
lso related to the ratio of the diastolic area of the RV and
eft ventricle (LV) and to pericardial effusion during
chocardiography.
Williams et al. (137) evaluated NT-proBNP, 6MWD,
emodynamics or tricuspid gradient, and survival in 109
atients with systemic sclerosis (SSc). Sixty-eight subjects
ad PAH, and 41 did not. In patients with normal PAP,
-year survival was 100%, compared with 83.5% in those
ith SSc-PAH (p  0.05). Patients without PAH had a
ean NT-proBNP level of 139 pg/ml; those with SSc-
AH had a significantly higher mean NT-proBNP level of
,474 pg/ml (p  0.0002). Among patients with PAH, for
very order of magnitude increase in NT-proBNP level,
here was a 4-fold increased risk of death (p  0.002 for
aseline level and p  0.006 for follow-up level). Baseline
T-proBNP levels correlated positively with mPAP and
VR and inversely with 6MWD.
Andreassen et al. (138) assessed plasma NT-proBNP in
1 consecutive patients with pre-capillary PH. Compared
ith age-matched control subjects (n  10), NT-proBNP
as significantly greater in those with IPAH (n  16),
hronic pre-capillary PH associated with other diseases
n  26), and chronic thromboembolic disease (n  19),
nd was correlated with hemodynamic variables and func-
ional capacity. In 17 medically treated patients, a significant
ecrease in NT-proBNP levels correlated with improved
emodynamics. Baseline NT-proBNP was an independent
redictor of mortality.
Park et al. (139) examined BNP levels in 20 PAH
atients as a marker of response to epoprostenol therapy. A
ecrease in BNP level of50% during the first 3 months on
poprostenol was strongly predictive of event-free survival
p  0.003).
ummary of prognostic parameters. A variety of disease
haracteristics and diagnostic measurements have been
ound to be predictive of prognosis in patients with PAH,
ncluding etiology, therapeutic interventions, hemodynam-
cs (cardiac index and RAP), echocardiographic findings
pericardial effusion, RV-Tei index, TAPSE), exercise ca-
acity (6MWD, peak oxygen consumption), NYHA FC,
nd BNP levels.
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Diagnosis and Assessment of PAH June 30, 2009:S55–66ollow-up assessment. The follow-up of patients with
AH has never been standardized, and has not been
ncluded in current guidelines (140–142). Two different
ollow-up strategies can be identified: a clinical strategy and
goal-oriented strategy. It is not known which strategy is
uperior.
LINICAL STRATEGY. This strategy is based principally on
he symptoms and signs reported on clinical examination. If
he FC is considered satisfactory (WHO FC I and II) and
o signs of right heart failure are detected, no changes in
herapy are proposed (143). Noninvasive examinations can
lso be included—for example, electrocardiography, chest
adiography, echocardiography, and 6MWD—but no pre-
pecified goals are considered, and results are used for
onfirming clinical stability or deterioration. In this case, the
ntervals between patient evaluations are variable, ranging
rom 3 to 6 months.
OAL-ORIENTED STRATEGY. Goal-oriented therapy has been
roposed to optimize treatment (144–146). The objective is
o correct parameters considered prognostically relevant and
o escalate treatment until a threshold is reached. Goal-
riented therapy requires: 1) identification of the parameters
o be measured; 2) establishment of levels to be achieved for
ach parameter; and 3) intervals of assessments. In an
xample described by Hoeper (144), patients were assessed
y 6MWD or CPET; goals were 6MWD 380 m, peak
xygen consumption 10.4 ml/min/kg, and peak systolic
lood pressure120 mm Hg during exercise; intervals were
to 6 months. Treatments were escalated to triple combi-
ation therapy if required. This strategy led to better
urvival compared with historical control subjects.
A similar strategy, but with different parameters and
oals, has been used at the University of Bologna (146).
arameters considered relate to symptoms (World Health
rganization FC), functional capacity (6MWD), and RV
unction as assessed by RHC. The goals are FC I or II,
MWD 500 m in patients 50 years old and 380 m in
lder patients, with RAP 10 mm Hg, and cardiac index
2.5 l/min/m2. Assessments are performed at baseline and
fter 3 to 4 months of first-line treatment. If the goals are
eached, the patient is followed up at 3- to 4-month
ntervals with a noninvasive approach. In case of subsequent
eterioration, hemodynamic confirmation is required. If the
rst-line treatment is not sufficient to reach the pre-
pecified goals, combination therapy is initiated and a
ubsequent evaluation is performed after 3 to 4 months.
oninvasive follow-up is carried out in cases of goal
ulfillment. In cases with nonsatisfactory results, triple
ombination therapy is initiated and patients are considered
or transplantation.
V function in PAH. The usual cause of death in PAH is
V failure. Both diastolic (147,148) and systolic (148)
ysfunction are likely contributors to RV failure. Diastolic
V dysfunction is thought to be related to RV hypertrophynd/or chronic pressure overload, with prolonged isovolu- aetric relaxation time (148,149) being a prominent feature.
ith systolic RV dysfunction, isovolumetric contraction
ime is prolonged and ejection time is shortened. An
chocardiographic, Doppler-derived index of combined RV
ystolic and diastolic function correlates with symptoms
149) and seems to be a predictor of survival in patients with
AH (148). Evidence of advanced clinical disease in pa-
ients with PAH is apparent, with elevated jugular venous
ressure, presence of a third heart sound (S3), and periph-
ral edema. Combined with increasing symptoms, decreased
V contractility, elevated RAP, and decreased CO, these
ndings suggest decompensated RV function.
It is difficult to assess the inotropic properties of prosta-
oids because of the strong vasodilative effects of these
ubstances. Epoprostenol has a positive inotropic effect on
he RV (150), but this may be caused by baroreflex activa-
ion. In isolated cardiomyocytes, treprostinil per se had no
ositive inotropic effects, but it significantly amplified the
ositive inotropic effects of catecholamines (151). This
ffect of prostanoids, along with inhibition of platelet
ggregation and smooth muscle cell contraction and prolif-
ration (152,153), may be in part responsible for its clinical
enefit. A PAH treatment strategy based on measures that
etter reflect RV function may be superior to the traditional
trategies outlined in consensus guidelines.
uture Directions
reatment escalation. EXERCISE CAPACITY. Aerobic exer-
ise capacity in PAH may be largely dependent on maxi-
um CO and on the maximum flow output of the RV. Gas
xchange function of the lungs in PAH is often normal or
ear normal. Rest- and exercise-induced hypoxemia are
aused by a decreased mixed venous oxygenation caused by
ow CO (154) or right-to-left intracardiac shunting. The
MWD has served well as a primary end point in most of
he RCTs of new therapies in PAH (140) and is a potent
redictor of functional state and survival (104,105,124).
wo important questions remain concerning exercise capac-
ty in PAH: 1) What is the minimal change in 6MWD
ffectively perceived by the patients as improvement or
eterioration? (In patients with chronic obstructive pulmo-
ary disease it was 54 m [155].) 2) What is the contribution
f respiratory and skeletal muscle weakness as well as joint,
one, neurological, and psychological factors to aerobic
xercise capacity in PAH?
CHOCARDIOGRAPHY. Echocardiography can be important
n the evaluation of RV function. The most relevant
easures are RV and LV surface areas, the eccentricity
ndex on parasternal short axis views, the Tei index (the
atio of the sum of isovolumic contraction and relaxation
imes divided by ejection time), TAPSE, inferior vena cava
imensions and inspiratory collapsibility, the presence and
agnitude of a pericardial effusion, RV and LV diastolic
unction estimated on tissue Doppler imaging of tricuspid
nd mitral annuli, and systolic function on tissue Doppler
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June 30, 2009:S55–66 Diagnosis and Assessment of PAHmaging measure of tricuspid annular systolic velocity S
ave (117,119,121,148,156–159). All are, to a variable
egree, sensitive to prognosis (117–119,121,148,157) and
herapeutic interventions (156,160).
NVASIVE HEMODYNAMICS. Right heart catheterization with
he measurement of PAP, CO, RAP, and pulmonary
rterial wedge pressure remains the gold standard for the
iagnosis of PAH (140,161). Possible areas for improve-
ent include the measurement of PAP at several levels of
ow to derive pulmonary vascular pressure–flow relationships
hat would improve the assessment of pulmonary vascular
unction and that might prove useful for diagnosis of latent
AH and for understanding the effects of therapy (162,163).
maging: a developing magnetic resonance imaging
ra? Magnetic resonance imaging is useful in the noninva-
ive assessment of the right heart in PH (164–167). It
rovides excellent spatial resolution, and virtually any plane
f cross section can be obtained. Direct assessment of
ardiac volumes, muscular mass, and function is possible.
recise flow measurements in the heart and great vessels can
e made using velocity-encoded imaging. Interobserver
ariability is low, which makes magnetic resonance imaging
potential tool for follow-up assessment (168,169). The
ERAPH (Sildenafil versus Endothelin Receptor Antagonist
or Pulmonary Hypertension) study used CMR to compare the
ffect of bosentan and sildenafil on RV hypertrophy (170).
Figure 1 Univariate Analysis of the Change in Variables, Includ
Imaging Data After 1-Year Follow-Up as a Potential Pr
6MWT  6-min walk test; IPAH  idiopathic pulmonary arterial hypertension; LV 
ular ejection fraction; NYHA  New York Heart Association; PA  pulmonary artery
RVEDVI  right ventricular end-diastolic volume index; RVEF  right ventricular eje
pean Society of Cardiology.hree-dimensional flow mapping of the central pulmonary
rtery may allow assessment of mPAP (171).
The first attempt to assess the value of CMR for
onitoring mortality risk in patients with PAH was made
y Van Wolferen et al. (172). Assessed at baseline, RV
troke volume index 26 ml/m2, RV end-diastolic volume
83 ml/m2, and LV end-diastolic volume 41 ml/m2 each
ndicated better survival. In a multivariate analysis, only
MWD added independently to the prognostic message
rovided by these CMR variables. Importantly, progressive
ilatation of the RV, as well as a decrease in LV diastolic
olume and a further decrease in RV stroke volume at 1-year
ollow-up, were related to worse long-term outcome (172)
Fig. 1).
V and PA/RV interactions. Chronic PH results from an
ncrease in PVR, which is a simple measure of opposition to
he mean component of flow. However, given the low
esistance/high compliance nature of pulmonary circulation,
he pulsatile component of hydraulic load is also critical.
everal studies have documented the relationship between
ulsatile pressure and flow (impedance) (173–176). These
tudies have shown that pulsatile load is increased in chronic
H. This abnormal pulsatile load may have detrimental
ffects on ventricular–vascular coupling, unfavorably loading
he still-ejecting RV. Impedance is a measure of the
pposition to the pulsatile components of flow. The role of
ulmonary arterial input impedance has been under-
agnetic Resonance
or of Mortality in IPAH
entricle; LVEDVI  left ventricular end-diastolic volume index; LVEF  left ventric-
 pulmonary vascular resistance index; RA  right atrium; RV  right ventricle;
raction. Reproduced from van Wolferen et al. (172) by permission of the Euro-ing M
edict
left v
; PVRI
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Diagnosis and Assessment of PAH June 30, 2009:S55–66ecognized in the past; however, there are compelling
easons why this should be evaluated (173–178).
Cardiomyocyte hypertrophy has been considered an
daptive response to increased load, such as hypertension or
ressure overload, because it normalizes the increase in wall
tress induced by mechanical overload (179). Prolongation
f this hypertrophic response leads to contractile dysfunc-
ion and heart failure. The distinctions between physiologic
nd pathologic hypertrophy are many (180).
There is emerging interest in determining the effect of
herapy on RV function. Phosphodiesterase-5A expression
s increased in the RVs of patients with PAH, and animal
odels suggest that inhibition of the enzyme results in
notropic activity (181). Magnetic resonance imaging-based
tudies have shown that acute sildenafil treatment promotes
V relaxation (147). Several other studies in animal models
ave shown improved RV systolic and diastolic function in
esponse to acute and chronic treatment with prostacyclin
nalogs, phosphodiesterase-5A inhibitors, and endothelin-
eceptor antagonists (181,182). Further studies are needed to
ranslate these observations into therapies for people with PH.
ummary
s new therapies have been developed for PAH, screening,
rompt diagnosis, and accurate assessment of disease sever-
ty have become increasingly important. A clear definition
f PH and the development of a rational approach to
iagnostic assessment and follow-up using both conven-
ional and new tools will be essential to deriving maximal
enefit from our expanding therapeutic armamentarium.
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